Drug intelligence / Profile preview

SA-009

Development stage: Preclinical
Lead developer: Sanopeutics

Overview

SA-009 is an early-stage oncology drug candidate being developed by Sanopeutics. As of early 2026, the asset is in the discovery or preclinical screening phase. Specific details regarding its molecular target, modality (such as small molecule or monoclonal antibody), and the specific types of cancer it is intended to treat have not been publicly disclosed by the company. It is part of a broader pipeline at Sanopeutics that includes candidates for metabolic and infectious diseases.

Beyond the preview

Go deeper on SA-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-009.

Explore the full profile